The CRI Anna-Maria Kellen Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis of cancer cell therapies based on information collected from numerous trusted and publicly available sources. We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication. 

Cancer Cell Therapy Landscape

 

Interactive dashboard: The top graph serves as the filter to curate the following two graphs. Seven different classes of cell therapies are defined based on their mechanism of actions. More details and other analyses can be found in the Nature Reviews Drug Discovery article published in May 2020.

Cancer Cell Therapy Analysis Publications

The most recent cancer cell therapy landscape publication is "Cancer cell therapies: The clinical trial landscape" in Nature Reviews Drug Discovery (May 2020).

Read more IO landscape publications 

Please note that all landscape dashboards are integrated with the CRI iAtlas for further exploration of the molecular targets. 

IO Landscapes

Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.

Subscribe to our email newsletter to receive the latest updates on our landscape analyses.

Do you want more information on the Clinical Accelerator? Contact us

*Immunotherapy results may vary from patient to patient.

Top